@article{a58d71bbccb14242be51c4c7517bf18a,
title = "ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use",
abstract = "In appropriate patients oral antiplatelet therapy decreases ischemic risks, but this therapy may increase bleeding complications. Of the major bleeding that occurs, the largest proportion is due to GI hemorrhage. Concomitant use of NSAIDs further raises the risk of GI bleeding. Gastroprotection strategies consist of use of PPIs in patients at high risk of GI bleeding and eradication of H. pylori in patients with a history of ulcers. Communication between cardiologists, gastroenterologists, and primary care physicians is critical to weigh the ischemic and bleeding risks in an individual patient who needs antiplatelet therapy but who is at risk for or develops significant GI bleeding.",
author = "Bhatt, {Deepak L.} and James Scheiman and Abraham, {Neena S.} and Antman, {Elliott M.} and Chan, {Francis K.L.} and Furberg, {Curt D.} and Johnson, {David A.} and Mahaffey, {Kenneth W.} and Quigley, {Eamonn M.} and Harrington, {Robert A.} and Bates, {Eric R.} and Bridges, {Charles R.} and Eisenberg, {Mark J.} and Ferrari, {Victor A.} and Hlatky, {Mark A.} and Sanjay Kaul and Lindner, {Jonathan R.} and Moliterno, {David J.} and Debabrata Mukherjee and Schofield, {Richard S.} and Rosenson, {Robert S.} and Stein, {James H.} and Weitz, {Howard H.} and Wesley, {Deborah J.}",
note = "Funding Information: Peer Reviewer Representation Consulting Fees/Honoraria Speakers' Bureau Ownership/Partnership/Principal Research Institutional or Other Financial Benefit Expert Witness or Consultant Dr. Eric R. Bates Official Reviewer—ACCF Task Force on Expert Consensus Documents • Sanofi-Aventis None None None None None Dr. Craig B. Clark Official Reviewer—ACCF Board of Governors None None None None None None Dr. Robert A. Harrington Official Reviewer—ACCF Board of Trustees • Bayer ⁎ • Bristol-Myers Squibb • Sanofi-Aventis None None • AstraZeneca ⁎ • Bayer ⁎ • Bristol-Myers Squibb ⁎ • Sanofi-Aventis ⁎ None None Dr. John Inadomi Official Reviewer—ACG • AstraZeneca • TAP Pharmaceuticals None None None None None Dr. Philip Katz Official Reviewer—ACG • AstraZeneca ⁎ • Horizon Therapeutics • TAP Pharmaceuticals • AstraZeneca ⁎ • Santarus • TAP Pharmaceuticals None None None None Dr. Laurence Sperling Official Reviewer—AHA None None None None None None Dr. Daniel I. Simon Official Reviewer—AHA • Sanofi-Aventis None None None None None Dr. Jeffrey S. Berger Content Reviewer—ACCF Prevention Committee None None None None None None Dr. Roger S. Blumenthal Content Reviewer—ACCF Prevention Committee None None None None None None Dr. Jeffrey J. Cavendish Content Reviewer—ACCF Prevention Committee None • Bristol-Myers Squibb/Sanofi-Aventis ⁎ None None None None Dr. Jose G. Diez Content Reviewer—ACCF Cardiac Catheterization and Intervention Committee • Sanofi-Aventis None • Sanofi-Aventis None None None Dr. Steven P. Dunn Content Reviewer—ACCF Prevention Committee None None None None None None Dr. Pamela B. Morris Content Reviewer—ACCF Prevention Committee • AstraZeneca • Pfizer • Takeda Pharmaceuticals North America None None None None None Dr. Srihari S. Naidu Content Reviewer—ACCF Cardiac Catheterization and Intervention Committee None None None None None None Dr. Robert S. Rosenson Content Reviewer—ACCF Task Force on Clinical Expert Consensus Documents None • AstraZeneca ⁎ None • AstraZeneca ⁎ None None Dr. Nanette K. Wenger Content Reviewer—ACC/AHA Guidelines on the Management of Patients With Unstable Angina/NSTEMI • AstraZeneca • Pfizer • Schering-Plough ⁎ None None • Pfizer ⁎ • Sanofi-Aventis ⁎ None None Ms. Marie J. Williams Content Reviewer—ACCF Cardiac Catheterization and Intervention Committee None None None None None None This table represents the relationships of peer reviewers with industry and other entities that were reported as relevant to this topic during the document development process. It does not necessarily reflect relationships at the time of publication. Participation in the peer review process does not imply endorsement of this document. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, ownership of $10 000 or more of the fair market value of the business entity, or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. ACC indicates American College of Cardiology; ACCF, American College of Cardiology Foundation; ACG, American College of Gastroenterology; AHA, American Heart Association; NHLBI, National Heart, Lung, and Blood Institute; NSAID, nonsteroidal anti-inflammatory drugs; and NSTEMI, non–ST-segment elevation myocardial infarction. ⁎ Significant (greater than $10 000) relationship. ",
year = "2008",
month = nov,
doi = "10.1111/j.1572-0241.2008.02216.x",
language = "English (US)",
volume = "103",
pages = "2890--2907",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "11",
}